FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Morrone Louis H.  (Last) (First) (Middle)  100 ABBOTT PARK ROAD  (Street)						2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ ABT ]  3. Date of Earliest Transaction (Month/Day/Year) 02/21/2024  4. If Amendment, Date of Original Filed (Month/Day/Year)								(Che	, , , , , , , , , , , , , , , , , , ,					
(City)	ΓPARK I		(Zip)		Rı		X Form filed by One Reporting Per Form filed by More than One Re Person  e 10b5-1(c) Transaction Indication										one Repo	rting		
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			Execution Date,		r, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owner following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership						
					/2024			Code	v	Amount 12,309	(A) or (D) Price			Transact (Instr. 3	Reported Fransaction(s) Instr. 3 and 4)		D	(Instr. 4)		
Common shares without par value 02/21.  Common shares without par value				1/2024			A		12,309	309 <sup>(1)</sup> A		\$0		2,556 <sup>(2)</sup>		I	Profit Sharing Trust			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date	3A. Deemee Execution I if any (Month/Day	Date,	4. Fransa Code (I				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Nu of	nount ımber nares						
Option (right to buy) <sup>(3)</sup>	\$116.98	02/21/2024			A		46,257		02/21/202	5 0	02/20/2034	Common Shares	46	5,257	\$0	46,257	7	D		

## **Explanation of Responses:**

- 1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- 2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2024.
- 3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,419 on February 21, 2025, 15,419 on February 21, 2026, and 15,419 on February 21, 2027.

/s/ Louis H. Morrone by Jessica 02/23/2024 H. Paik, Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.